The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
GLP-1 metabolite GLP-1(9–36) is a systemic inhibitor of mouse and human pancreatic islet glucagon secretion
Open accessAbstract
Aims/hypothesis: Diabetes mellitus is associated with impaired insulin secretion, often aggravated by oversecretion of glucagon. Therapeutic interventions should ideally correct both defects. Glucagon-like peptide 1 (GLP-1) has this capability but exactly how it exerts its glucagonostatic effect remains obscure. Following its release GLP-1 is rapidly degraded from GLP-1(7–36) to GLP-1(9–36). We hypothesised that the metabolite GLP-1(9–36) (previously believed to be biologically inactive) exerts a direct inhibitory effect on glucagon secretion and that this mechanism becomes impaired in diabetes. Methods: We used a combination of glucagon secretion measurements in mouse and human islets (including islets from donors with type 2 diabetes), total internal reflection fluorescence microscopy imaging of secretory granule dynamics, recordings of cytoplasmic Ca 2+ and measurements of protein kinase A activity, immunocytochemistry, in vivo physiology and GTP-binding protein dissociation studies to explore how GLP-1 exerts its inhibitory effect on glucagon secretion and the role of the metabolite GLP-1(9–36). Results: GLP-1(7–36) inhibited glucagon secretion in isolated islets with an IC 50 of 2.5 pmol/l. The effect was particularly strong at low glucose concentrations. The degradation product GLP-1(9–36) shared this capacity. GLP-1(9–36) retained its glucagonostatic effects after genetic/pharmacological inactivation of the GLP-1 receptor. GLP-1(9–36) also potently inhibited glucagon secretion evoked by β-adrenergic stimulation, amino acids and membrane depolarisation. In islet alpha cells, GLP-1(9–36) led to inhibition of Ca 2+ entry via voltage-gated Ca 2+ channels sensitive to ω-agatoxin, with consequential pertussis-toxin-sensitive depletion of the docked pool of secretory granules, effects that were prevented by the glucagon receptor antagonists REMD2.59 and L-168049. The capacity of GLP-1(9–36) to inhibit glucagon secretion and reduce the number of docked granules was lost in alpha cells from human donors with type 2 diabetes. In vivo, high exogenous concentrations of GLP-1(9–36) (>100 pmol/l) resulted in a small (30%) lowering of circulating glucagon during insulin-induced hypoglycaemia. This effect was abolished by REMD2.59, which promptly increased circulating glucagon by >225% (adjusted for the change in plasma glucose) without affecting pancreatic glucagon content. Conclusions/interpretation: We conclude that the GLP-1 metabolite GLP-1(9–36) is a systemic inhibitor of glucagon secretion. We propose that the increase in circulating glucagon observed following genetic/pharmacological inactivation of glucagon signalling in mice and in people with type 2 diabetes reflects the removal of GLP-1(9–36)’s glucagonostatic action. Graphical Abstract:
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





![Fig. 6 GLP-1(9–36) inhibits both depolarisation- and agonist-induced glucagon secretion. (a) Glucagon secretion at 3.6 or 70 mmol/l extracellular K+ ([K+]o) in the absence or presence of GLP-1(9–36) as indicated. Each data point represents a unique group of 12 islets isolated from 6 mice). Glucagon secretion has been normalised to that at 1 mmol/l glucose (1=16.9±1.9 pg islet−1 h−1). ***p<0.001 vs 1 mmol/l glucose at 3.6 mmol/l [K+]o; †††p<0.001 vs 70 mmol/l [K+]o alone. (b) Glucagon secretion at 1 mmol/l glucose in the absence or presence of a cocktail of AAs (2 mmol/l each of glutamine, alanine and arginine) and GLP-1(9–36) as indicated. Each data point represents a unique group of 12 islets isolated from 10 mice. Glucagon secretion has been normalised to that at 1 mmol/l glucose (1=36.5±7.3 pg islet−1 h−1). ***p<0.001vs no AAs; †p<0.05 vs 6 mmol/l AA alone. (c) As for (b) but testing the effects of isoprenaline (1=11±1.9 pg islet−1 h−1; 9 mice). ***p<0.001 vs 1 mmol/l glucose; †††p<0.001 vs isoprenaline. Statistical significance in (a–c) was estimated using one-way ANOVA with Tukey’s post hoc test](https://figures.cochat.ai/paper-figures/bf73e64ed7704740ae675dc377017bd9/glp-1-metabolite-glp-1-936-is-a-systemic-inhibitor-of-mouse-and-human-pancreatic-figure-6.jpg)

![Fig. 8 Impact of P/Q-type Ca2+ channel inhibition and type 2 diabetes on GLP-1(9–36)-induced granule undocking. (a) Glucagon secretion measured at 1 mmol/l glucose in the absence and presence of 10 pmol/l GLP-1(9–36) under control conditions (without ω-agatoxin) and in the presence of ω-agatoxin (200 nmol/l) as indicated. Note that the blocker, when added as indicated, was present in both the absence and presence of GLP-1(9–36). Each data point represents a unique group of 12 islets isolated from 6 mice. Glucagon secretion has been normalised to that at 1 mmol/l glucose (1=6.0±0.2 pg islet−1 h−1). **p<0.01 vs 1 mmol/l glucose; †p<0.05 vs 1 mmol/l glucose and ω-agatoxin (one-way ANOVA followed by Dunnet’s post hoc test). (b) Depolarisation-evoked increases in [Ca2+]i elicited by increasing extracellular K+ ([K+]o) from 3.6 to 70 mmol/l in the presence of 10 μmol/l isradipine (to block L-type Ca2+ channels). Under these experimental conditions depolarisation-induced Ca2+ entry will reflect P/Q-type Ca2+ channel activity. GLP-1(9–36) (10 pmol/l) and ω-agatoxin were included in the medium as indicated (n=139 cells from 4 mice). (c) Granule density measured in the absence or presence of ω-agatoxin (200 nmol/l). *p<0.05. (d) Effects of GLP-1(9–36) in the presence of ω-agatoxin (200 nmol/l). (e) As for (c) but testing the effect of diazoxide (0.2 mmol/l). Control cells were incubated in the presence of 0.1% DMSO (solvent used for diazoxide). ***p<0.001 vs 1 mmol/l glucose (Student’s t test). (f) Granule density measured in human alpha cells in the absence or presence of 10 pmol/l GLP-1(9–36) (measured after 15 min). Mean values ± SEM of 28 GLP-1(9–36)-treated and 27 control alpha cells from 3 donors. ***p<0.001 vs control (Student’s t test). (g) As for (f) but in alpha cells from donors with type 2 diabetes. Mean values ± SEM of 43 GLP-1(9–36)-treated and 31 control cells from two donors. ***p<0.001 vs control. (h) Effects of GLP-1(9–36) on glucagon secretion in islets from cadaveric healthy donors. Each data point represents a unique group of 12 islets isolated from 13 healthy donors (black bars and grey symbols) and 3 donors with type 2 diabetes (red bars and symbols). Glucagon secretion has been normalised to that at 1 mmol/l glucose (1=7.01±0.91 and 2.41±0.62 pg islet−1 h−1 from experiments carried out on islets from donors without and with type 2 diabetes, respectively). ***p<0.001 vs no GLP-1(9–36) in islets from healthy donors (one-way ANOVA with Dunnett’s post hoc test)](https://figures.cochat.ai/paper-figures/51a56fd45bb946feaeab460fdecfb3e6/glp-1-metabolite-glp-1-936-is-a-systemic-inhibitor-of-mouse-and-human-pancreatic-figure-8.jpg)

![Fig. 10 Regulation of glucagon secretion by physiological concentrations of GLP-1(7–36) and (9–36) via paracrine and intrinsic alpha cell mechanisms. (a) GLP-1(7–36) inhibits glucagon secretion by dual effects (indicated by 1 and 2). (1) Activation of GLP-1Rs in beta and delta cells stimulates the release of paracrine inhibitors of glucagon secretion. This mechanism is suppressed by pharmacological [using exendin(9–39)] or genetic inactivation of the GLP-1R. (2) GLP-1(9–36), generated by (DPP-4-mediated) degradation of GLP-1(7–36), results in activation of an inhibitory GTP-binding protein (Gi/o), culminating (via undocking of secretory granules [SG] below the plasma membrane) in suppression of glucagon secretion. This mechanism is not affected by genetic/pharmacological inactivation of the GLP-1R but is sensitive to pertussis toxin. It is not activated by exendin-4, which is more resistant to DPP-4-induced degradation than GLP-1(7–36). GLP-1(7–36) will activate both (1) and (2) but exogenous GLP-1(9–36) will only activate (2). (b) Concentration-dependent inhibition of glucagon secretion by GLP-1(9–36). Because of high circulating GLP-1(9–36) levels, administration of high exogenous GLP-1(9–36) will only have a marginal additional glucagonostatic effect (red arrow). GRAs lead to a large increase in circulating glucagon by reversing the glucagonostatic effects of endogenous GLP-1(9–36) (black arrow)](https://figures.cochat.ai/paper-figures/568be20662ec44ceae81e5cde5f940d2/glp-1-metabolite-glp-1-936-is-a-systemic-inhibitor-of-mouse-and-human-pancreatic-figure-10.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent studies show that GLP-1(9–36) can activate the inhibitory G protein (Gi/o), leading to the translocation of secretory granules (SG) beneath the cell membrane, thereby inhibiting glucagon secretion.241”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [241]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, this inhibitory effect is significantly weakened in patients with T2DM, indicating that its potential application in diabetes treatment requires further investigation.241”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [241]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In summary, GLP-1 lowers blood glucose levels and inhibits glucagon secretion through direct action on α-cells, promotion of insulin secretion, and regulation of gastrointestinal activity.241”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [241]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GLP-1(9–36) promotes the undocking of secretory granules (SG) by inhibiting the entry of Ca2+ through voltage-gated Ca2+ channels. As a result, GLP-1(9–36) reduces the number of granules available for exocytosis in α-cells, thereby decreasing the release of glucagon.241”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [241]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Recent studies have shown that GLP-1(9–36) is particularly effective at low glucose concentrations, with its inhibitory effect being similar to that of GLP-1(7-36).241”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [241]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ultrasensitive fluorescent proteins for imaging neuronal activity
Chen, T.-W., Wardill, T. J., Sun, Y., Pulver, S. R., Renninger, S. L., Baohan, A., Schreiter, E. R., Kerr, R. A., Orger, M. B., Jayaraman, V., et al. (2013) · Nature · doi:10.1038/nature12354 · Cited by 6,474 · cited 1×
“A transgenic reporter mouse model that expresses a genetically encoded Ca 2+ indicator GCaMP6-fast variant [11] (GCaMP6f) specifically in alpha cells (Gcg-GCaMP6f) was generated by crossing Gcg CreERT2 mice [12] (42277-JAX; Jackson Laboratory) (which express a tamoxifen-inducible form of Cre from…”
MethodThe Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Madisen, L., Garner, A. R., Shimaoka, D., Chuong, A. S., Klapoetke, N. C., Li, L., van der Bourg, A., Niino, Y., Egolf, L., Monetti, C., et al. (2015) · Neuron · doi:10.1016/j.neuron.2015.02.022 · Cited by 1,114
Tissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans
Ørskov, C., Rabenhøj, L., Wettergren, A., Kofod, H., & Holst, J. J. (1994) · Diabetes · doi:10.2337/diab.43.4.535 · Cited by 919
Scrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793 · cited 1×
“In addition, Glp1r −/− mice [10] were used (sex-and age-matched wild-type littermates were used as controls).”
MethodDecay Rates of Human mRNAs: Correlation With Functional Characteristics and Sequence Attributes
Yang, E., van Nimwegen, E., Zavolan, M., Rajewsky, N., Schroeder, M., Magnasco, M., & Darnell, J. E. (2003) · Genome Research · doi:10.1101/gr.1272403 · Cited by 606
The essential role of glucagon in the pathogenesis of diabetes mellitus
Unger, R., & Orci, L. (1975) · The Lancet · doi:10.1016/s0140-6736(75)92375-2 · Cited by 599
TRUPATH, an open-source biosensor platform for interrogating the GPCR transducerome
Olsen, R. H. J., DiBerto, J. F., English, J. G., Glaudin, A. M., Krumm, B. E., Slocum, S. T., Che, T., Gavin, A. C., McCorvy, J. D., Roth, B. L., et al. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-0535-8 · Cited by 544
DiGruccio, M. R., Mawla, A. M., Donaldson, C. J., Noguchi, G. M., Vaughan, J., Cowing-Zitron, C., van der Meulen, T., & Huising, M. O. (2016) · Molecular Metabolism · doi:10.1016/j.molmet.2016.04.007 · Cited by 353
Blodgett, D. M., Nowosielska, A., Afik, S., Pechhold, S., Cura, A. J., Kennedy, N. J., Kim, S., Kucukural, A., Davis, R. J., Kent, S. C., et al. (2015) · Diabetes · doi:10.2337/db15-0039 · Cited by 330
Cited by
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
“232,233,241,259 (Fig.”
BackgroundGLP1R and GIPR expression and signaling in pancreatic alpha cells, beta cells and delta cells
Shilleh, A. H., Viloria, K., Broichhagen, J., Campbell, J. E., & Hodson, D. J. (2024) · Peptides · doi:10.1016/j.peptides.2024.171179 · Cited by 39
Metadata
- Authors
- Gandasi, N. R., Gao, R., Kothegala, L., Pearce, A., Santos, C., Acreman, S., Basco, D., Benrick, A., Chibalina, M. V., Clark, A., Guida, C., Harris, M., Johnson, P. R. V., Knudsen, J. G., Ma, J., Miranda, C., Shigeto, M., Tarasov, A. I., Yeung, H. Y., Thorens, B., Asterholm, I. W., Zhang, Q., Ramracheya, R., Ladds, G., & Rorsman, P.
- Affiliations
- Indian Institute of Science Bangalore (IN)
- Churchill Hospital (GB)
- University of Gothenburg (SE)
- University of Cambridge (GB)
- University of Lausanne (CH)
- University of Copenhagen (DK)
- University of Ulster (GB)
- Corresponding author
- Rorsman, Patrik
- ORCID
- Gandasi, Nikhil R.
- Gao, Rui
- Kothegala, Lakshmi
- Pearce, Abigail
- Santos, Cristiano
- Acreman, Samuel
- Basco, Davide
- Benrick, Anna
- Chibalina, Margarita V.
- Clark, Anne
- Guida, Claudia
- Harris, Matthew
- Johnson, Paul R. V.
- Knudsen, Jakob G.
- Ma, Jinfang
- Miranda, Caroline
- Shigeto, Makoto
- Tarasov, Andrei I.
- Yeung, Ho Yan
- Thorens, Bernard
- Asterholm, Ingrid W.
- Zhang, Quan
- Ramracheya, Reshma
- Ladds, Graham
- Rorsman, Patrik
- Venue
- Diabetologia
- Published
- 2023-12-21
- Volume
- 67
- Issue
- 3
- Pages
- 528-546
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- PMC
- PMC10844371
- OpenAlex
- W4390061924
- Cited by
- 31
- References
- 67
- Citations by year
- 2026: 7 · 2025: 10 · 2024: 14
- FWCI
- 8.28
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Diabetologia (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by)
- Ulster University Research Portal (Ulster University) (acceptedVersion, other-oa)
- SERVAL (Université de Lausanne) (acceptedVersion, other-oa)
- IRIS (submittedVersion, cc-by)
- Apollo (University of Cambridge) (submittedVersion, cc-by)
- Apollo (cc-by)
- Funders
- Vetenskapsrådet (2013-7107, 2020-01463, 2020-02485)
- University of Gothenburg
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Keywords
- GLP-1(7-36), glucagon secretion, pancreatic islets, alpha cells, type 2 diabetes, GLP-1 receptor, secretory granules, protein kinase A, glucagon receptor, beta-adrenergic stimulation, calcium signaling
- MeSH terms
- Diabetes Mellitus, Type 2, Glucagon, Humans, Hypoglycemia, Insulin, Islets of Langerhans, Peptide Fragments, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: GLP-1 metabolite GLP-1(9–36) is a systemic inhibitor of mouse and human pancreatic islet glucagon secretion. https://app.cochat.ai/papers/10.1007/s00125-023-06060-w
- The paper
- Gandasi, N. R., Gao, R., Kothegala, L., Pearce, A., Santos, C., Acreman, S., Basco, D., Benrick, A., Chibalina, M. V., Clark, A., Guida, C., Harris, M., Johnson, P. R. V., Knudsen, J. G., Ma, J., Miranda, C., Shigeto, M., Tarasov, A. I., Yeung, H. Y., . . . Rorsman, P. (2024). GLP-1 metabolite GLP-1(9–36) is a systemic inhibitor of mouse and human pancreatic islet glucagon secretion. Diabetologia. https://doi.org/10.1007/s00125-023-06060-w
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.